What Happened?
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Drug Development Inputs & Services company Medpace (NASDAQ: MEDP) fell 3%. Is now the time to buy Medpace? Access our full analysis report here, it’s free for active Edge members.
- Research Tools & Consumables company Revvity (NYSE: RVTY) fell 3.1%. Is now the time to buy Revvity? Access our full analysis report here, it’s free for active Edge members.
Zooming In On Revvity (RVTY)
Revvity’s shares are somewhat volatile and have had 11 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 10 days ago when the stock gained 3.9% on the news that reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
Revvity is down 20.7% since the beginning of the year, and at $88.82 per share, it is trading 30% below its 52-week high of $126.84 from January 2025. Investors who bought $1,000 worth of Revvity’s shares 5 years ago would now be looking at an investment worth $692.15.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
